

Saroglitazar

Chemical Properties

CAS No. : 495399-09-2


Formula: C₂₅H₂₉NO₄S

Molecular Weight: 439.57

Keep away from direct sunlight, Store under nitrogen

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Saroglitazar (Lipaglyn) is an agonist of PPAR with EC ₅₀ values of 0.65 pM and 3 nM for PPAR α and PPAR γ .
Targets(IC ₅₀)	PPAR
In vivo	In db/db mice, Saroglitazar (0.01-3 mg/kg; orally) reduces serum triglycerides, free fatty acids, and glucose in a dose-dependent manner (ED ₅₀ = 0.05, 0.19, and 0.19 mg/kg). Saroglitazar (1 mg/kg) significantly reduces serum insulin and AUC-glucose

Solubility Information

Solubility	DMSO: 22.5 mg/mL (51.19 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.55 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.275 mL	11.3748 mL	22.7495 mL
5 mM	0.455 mL	2.275 mL	4.5499 mL
10 mM	0.2275 mL	1.1375 mL	2.275 mL
50 mM	0.0455 mL	0.2275 mL	0.455 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jain MR, et al. Saroglitazar, a novel PPAR α / γ agonist with predominant PPAR α activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. *Pharmacol Res Perspect.* 2015 Jun;3(3):e00136.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481